Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon May 20, 2018 10:37am
173 Views
Post# 28057930

RE:RE:RE:Echelon Partners

RE:RE:RE:Echelon Partners

100 after 2.5 weeks. 

Prescriptions accelerating.

1st week of July is 7 weeks away.

I’ll go with 450-500 prescriptions.

Is that not just the low hanging Fuzeon fruit anyway?

bfw




palinc2000 wrote:
SPCEO1 wrote:
SPCEO1 wrote: Bloomberg is reporting that Echelon published something today but the analyst did not change wither his target price of C$12.50 or his Buy recommendation. Since those two things don't add up, I suspect we will see one of them change soon.   


I believe a short, positive note in his weekly report is what Bloomberg was picking up. In it, the Echelon analyst seemed to indicate he would be waiting until Q2 results are reported before making any changes to his model or rating. But that is me reading between the lines, which doesn't always provide accurate results. After the stock's big run, it may well consolidate a bit and ease the pressure on this analyst to address the obvious problem with his Buy rating, his target price and the current stock price. However, if the stock price is stable or rises further, I am not sure he can postpone addressing the problem until early July. The same is true for the Canaccord analyst. CIBC has a target price of C$15, so his rating still makes sense. NBF at C$14 barely makes any sense. Mackie at C$19.50 has a price target that more comport both with reality and his rating.


If we had from TH something similar to the Federal Reserve Dot Plot that would make analysts job much easier and ours also.But that wont happen!!
However I believe if we are provided with enough dots that we will be in a position to evaluate the steepness of the demand curve

For now all we have is about 100 patients on May 16 ....We should be provided additional dots for end of May and possibly for  first week of July during the CC

Can anyone venture what the cumulative number of patients will be in the first week of July.?




Bullboard Posts